Aurobindo has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 4 of them, and has 1 filed or in development. Those brands earned $35.6B in 2025. Of the 70 makers we follow, 15 are lined up to copy more of these drugs.
| Drug | Aurobindo's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| EntrestoGeneric · Novartis · US LOE 2025 | FDA-approved 2 Sep 2026 | 2 on sale · 13 approvedof 15 other makers listed | $7.7B |
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 10 Apr 2025 | 1 on sale · 17 approvedof 19 other makers listed | ≈$5.3B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026; said it was eligible for 180-day shared exclusivity, which ended about 3 Oct 2026 | 2 on sale · 12 approvedof 14 other makers listed | $8.4B |
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 18 Apr 2023 | 2 on sale · 9 approvedof 11 other makers listed | $2.3B |
| Drug | Aurobindo's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| VraylarGeneric · AbbVie · US LOE 2029 | FDA-approved 16 Dec 2025, not marketed | 0 on sale · 0 approvedof 2 other makers listed | $3.6B |
| Drug | Aurobindo's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| RinvoqGeneric · AbbVie · US LOE 2037 | Filed with the FDA; settled Sep 2025; US entry allowed from Apr 2037. Assuming pediatric exclusivity is granted | 0 on sale · 0 approvedof 4 other makers listed | $8.3B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Aurobindo sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Aurobindo's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Aurobindo's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Aurobindo.